|
Market Closed -
TEL AVIV STOCK EXCHANGE
23:24:49 26/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 2,407.00 ILa | +0.42% |
|
+1.78% | +6.50% |
| 10-06 | Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel | MT |
| 10-06 | Kamada Ltd. Announces Expansion of Biosimilars Portfolio with Launch of Two Additional Products in Israel | CI |
Company Valuation: Kamada Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 920.4 | 615 | 1,280 | 1,271 | 1,304 | 1,383 | - | - |
| Change | - | -33.18% | 108.12% | -0.69% | 2.55% | 6.11% | - | - |
| Enterprise Value (EV) | 920.4 | 615 | 1,280 | 1,271 | 1,304 | 1,383 | 1,383 | 1,383 |
| Change | - | -33.18% | 108.12% | -0.69% | 2.55% | 6.11% | 0% | 0% |
| P/E | - | - | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.7x | 1.31x | 2.51x | 2.17x | 2.35x | 2.27x | 2.02x | 1.86x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.27x | 2.02x | 1.86x |
| EV / EBITDA | - | - | 0x | 0x | 0x | 9.11x | 6.99x | 6.54x |
| EV / EBIT | -0x | 0x | 0x | 0x | 0x | 13.7x | 10.9x | 9.64x |
| EV / FCF | -0x | - | -0x | 0x | 0x | 23.5x | 15.5x | 11.4x |
| FCF Yield | -4.52% | - | -0.43% | 10.5% | 3.73% | 4.26% | 6.44% | 8.77% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 340.3 | 469.1 | 510.9 | 586.9 | 555.7 | 608.5 | 685.4 | 745.7 |
| EBITDA 1 | - | - | 86.36 | 124.5 | 129.3 | 151.9 | 197.9 | 211.5 |
| EBIT 1 | -2.286 | 16.44 | 36.08 | 73.11 | 80.79 | 101.2 | 127.5 | 143.5 |
| Net income 1 | -7.323 | -8.417 | 29.7 | 52.73 | 62.2 | 83.39 | 101.3 | 113.4 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 20.55 | 13.72 | 22.27 | 22.11 | 22.60 | 23.97 | 23.97 | 23.97 |
| Nbr of stocks (in thousands) | 44,786 | 44,826 | 57,476 | 57,492 | 57,682 | 57,710 | - | - |
| Announcement Date | 15/3/22 | 15/3/23 | 6/3/24 | 5/3/25 | 11/3/26 | - | - | - |
1ILS in Million2
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 445M | |
| 37.06x | 13.1x | 27.8x | 0.54% | 1,135B | |
| 38.61x | 6.49x | 18.27x | 2.02% | 635B | |
| 36.46x | 8.38x | 17.33x | 2.41% | 505B | |
| 20.87x | 5.11x | 12.73x | 2.56% | 378B | |
| 105.89x | 5.92x | 25.41x | 2.34% | 358B | |
| 21.76x | 5.68x | 13.94x | 2.81% | 295B | |
| 22.43x | 4.53x | 12.94x | 1.95% | 266B | |
| 27.87x | 7.16x | 12.81x | 2.3% | 237B | |
| -45.48x | 6.98x | 27.06x | 2.11% | 193B | |
| Average | 29.50x | 7.04x | 18.70x | 2.12% | 400.41B | |
| Weighted average by Cap. | 35.23x | 8.29x | 20.40x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- KMDA Stock
- Valuation Kamada Ltd.
Select your edition
All financial news and data tailored to specific country editions
